Mirus Bio Corporation is a biopharmaceutical company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products. The company currently markets a range of innovative transfection and labeling reagents worldwide, and is developing therapies based on its proprietary Pathway IV ™ delivery protocol.
Pathway IV ™ is a clinically practical procedure based upon intravenous ("IV") delivery of plasmid DNA ("pDNA") to targeted limb muscle. With blood flow temporarily occluded by a tourniquet, a DNA solution is rapidly injected IV. This elevates the pressure within the occlusion zone, making the blood vessel wall more permeable and allowing the pDNA to migrate into the adjoining muscle cells. Blood flow is then restored to normal within a few minutes, with no adverse affects to the vasculature.
This quick, robust procedure is being used as an enabling platform that will provide first-in-class therapeutic treatments for muscular dystrophy, peripheral ischemia and anemia.
In this interview, AZoNano visits the Graphene Engineering and Innovation Centre to talk with Mark Dickie, Composite Applications Manager, about how the GEIC is helping to take graphene composite innovation out of the lab and into the wider industry.
In this interview, we speak with Stanford's Gu Group about their newly developed metal nanocluster-based material that's advancing nanoscale 3D printing.
Professor Andre Nel
In this interview, AZoNano speaks with Professor Andre Nel about his involvement in innovative research describing the development of a 'glass bubble' nanocarrier that could help drug formulations access pancreatic cancer cells.
The MiniCapt® Pro is a remote microbial air sampler that is ideal for the pharmaceutical manufacturing industry.
This product profile outlines the NanoRacer High-Speed AFM from Bruker JPK.
NMR spectroscopy is a characterization technique that is extensively used by chemical researchers.